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Aims Heart failure (HF) is a major public health concern worldwide. The diversity of HF makes it challenging to decipher the
underlying complex pathological processes using single biomarkers. We examined the association between urinary
peptides and HF with reduced (HFrEF), mid-range (HFmrEF) and preserved (HFpEF) ejection fraction, defined based
on the European Society of Cardiology guidelines, and the links between these peptide biomarkers and molecular
pathophysiology.
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Methods
and results
Analysable data from 5608 participants were available in the Human Urinary Proteome database. The urinary peptide
profiles from participants diagnosed with HFrEF, HFmrEF, HFpEF and controls matched for sex, age, estimated
glomerular filtration rate, systolic and diastolic blood pressure, diabetes and hypertension were compared applying
the Mann–Whitney test, followed by correction for multiple testing. Unsupervised learning algorithms were applied
to investigate groups of similar urinary profiles. A total of 577 urinary peptides significantly associated with HF
were sequenced, 447 of which (77%) were collagen fragments. In silico analysis suggested that urinary biomarker
abnormalities in HF principally reflect changes in collagen turnover and immune response, both associated with
fibrosis. Unsupervised clustering separated study participants into two clusters, with 83% of non-HF controls
allocated to cluster 1, while 65% of patients with HF were allocated to cluster 2 (P< 0.0001). No separation based
on HF subtype was detectable.
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Conclusions Heart failure, irrespective of ejection fraction subtype, was associated with differences in abundance of urinary
peptides reflecting collagen turnover and inflammation. These peptides should be studied as tools in early detection,
prognostication, and prediction of therapeutic response.
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Graphical Abstract
Clear differences between urinary peptides from patients with heart failure and controls are observed, indicating alterations in collagen turnover
and immune response; while there is a high similarity between urinary profiles among heart failure subtypes. COL1A1, collagen alpha-1(I) chain;
COL1A2, collagen alpha-2(I) chain; COL2A1, collagen alpha-1(II) chain; COL3A1, collagen alpha-1(III) chain; FGA, fibrinogen alpha chain; HF, heart
failure; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced
ejection fraction; IGF, insulin-like growth factor; UMOD, uromodulin.
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Introduction
Heart failure (HF) is a syndrome, not a discrete diagnosis, although
three subtypes, based on left ventricular ejection fraction (EF), are
commonly recognised. However, HF is likely to be far more hetero-
geneous. Multiple aetiologies (including ischaemic heart disease and
hypertension) may lead to abnormalities in the systolic and/or dias-
tolic function of the heart. Because of the similarity in the molecular
events underlying many of these clinical pathways, it is challenging















. subtypes of HF, indicating a need for a deeper understanding of
the molecular mechanisms leading to HF. Describing the complex
pathophysiology of HF using single biomarkers is challenging and
does not reflect the clinical and pathophysiological complexity of
the syndrome.
The application of proteome analysis to clinically relevant prob-
lems is an emerging and promising field of biomarker research.1
Previous studies using urinary proteome analysis2 have identified
urinary peptides strongly associated with renal damage, coronary
artery disease and left ventricular diastolic dysfunction.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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The aim of the present study was a comprehensive description
of molecular differences at the level of the urinary proteome
between individuals with HF and without HF, as well as between
HF subtypes. The focus was placed on peptides with high specificity
for HF based on the comparison between case and control groups
matched for kidney function, sex, age, blood pressure and the
presence of diabetes and hypertension.
Methods
Patient data
We extracted patient data from the Human Urinary Proteome
database of capillary electrophoresis mass spectrometry (CE-MS) data
on urinary peptides3,4 that at the time of the extraction contained
datasets from 50 651 individuals. Data were included in the study if:
(i) data on sex, age, estimated glomerular filtration rate (eGFR), sys-
tolic (SBP) and diastolic blood pressure (DBP), and diabetic status were
available; (ii) age was above 20 years; (iii) data passed quality control cri-
teria for CE-MS measurements, post-acquisition data processing and
calibration, as previously described.4 Exclusion criteria were diagno-
sis of cancer, solid organ transplantation, or intensive care unit stay at
the time of inclusion. Urine samples from 5608 participants (individu-
als with and without HF) were available. Overall, 1180 patients had HF
and 4428 patients did not have a diagnosis of HF.
Urine samples were obtained from the following studies: (i) STANIS-
LAS cohort study5; (ii) Hull LifeLab6; (iii) study on diagnostic and prog-
nostic utility of the proteomic classifier HF17; (iv) FLEMENGHO and
EPOGH8; (v) Generation Scotland cohort9; (vi) an echocardiographic
and cardiac biomarker study10; and (vii) cross-sectional multicentre
cohort study.11 Further details such as patients’ characteristics and
information on EF measurements, if applicable, are reported in the rele-
vant manuscripts. For 82% of HF patients, urine samples were collected
within 24 h of the assessment of the EF. For remaining HF patients,
timing was not recorded. The investigation conforms with the princi-
ples outlines in the Declaration of Helsinki12; all data were anonymized
and the study was approved by the ethics committee of the University
Aachen (EK163/19).
Data curation
Heart failure was defined using the European Society of Cardiology
(ESC) guidelines recommended at the time of patients’ recruitment.
In all cases, the diagnosis was based on the presence of symptoms
or signs of HF, caused by a structural and/or functional heart abnor-
mality. Patients with HF with missing measurements of EF or natri-
uretic peptides [N-terminal prohormone of B-type natriuretic peptide
(NT-proBNP) or B-type natriuretic peptide (BNP)] were excluded
(n = 154). Only patients with NT-proBNP or BNP >125 pg/mL or
>35 pg/mL were included. To account for an update in the ESC guide-
lines, the diagnosis of HF subtypes was assigned based on the EF
thresholds in the ESC recommendations13 [i.e. for HF with reduced
EF (HFrEF): EF <40%; for HF with mid-range EF (HFmrEF): EF ≥40 and
≤49; for HF with preserved EF (HFpEF): EF ≥50%]. Based on these cri-
teria, 515, 259 and 219 subjects with the diagnosis of HFrEF, HFmrEF
and HFpEF were identified, respectively.
Individuals without HF with NT-proBNP >300 pg/mL (or BNP
>100 pg/mL), EF <50% or with New York Heart Association (NYHA)
III–IV symptoms were excluded from the control group (n = 451).



















































































.. urine sampling had no known diagnosis of HF (n = 3977). The lat-
ter group included, among others, healthy individuals, patients with
chronic kidney disease (CKD), hypertension, diabetes or coronary
artery disease (or a combination of these pathologies). CKD was
defined based on the clinical diagnosis and/or on the kidney func-
tion (eGFR < 60 mL/min/1.73 m2). eGFR was estimated based on
the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation. Hypertension was diagnosed based on the use of antihyper-
tensive drugs, SBP of 140 mmHg or higher, and/or DBP of 90 mmHg or
higher.14 Patient selection and data curation are graphically depicted in
Figure 1A.
Case-control matching
Matching of cases to non-HF controls was performed in R (‘MatchIt’15).
A ‘nearest neighbour’ matching-method was applied, allowing for
discarding of datasets from both groups that were outside the
distance-measure and re-estimation of distance-measure after discard-
ing. Logistic regression was used to estimate the distance-measure
(default setting). Case-control matching at a 1:1 ratio was performed
based on sex, age, eGFR, SBP, DBP, and the presence of diabetes and
hypertension. HF patients were matched to non-HF controls. Those
patients were divided based on EF, followed by matching of the controls
selected from the group of controls already matched to the complete
HF cohort. Patients presenting with specific HF subtype were subse-
quently matched to each other. The following groups were matched
based on these variables: (i) HF vs. non-HF controls, (ii) HFrEF vs.
non-HF controls, (iii) HFmrEF vs. non-HF controls, (iv) HFpEF vs.
non-HF controls, (v) HFrEF vs. HFmrEF, (vi) HFmrEF vs. HFpEF, and
(vii) HFrEF vs. HFpEF. The schematic illustration of the matching is
presented in Figure 1B and online supplementary Figure S1.
Capillary electrophoresis mass
spectrometry
Preparation and measurements of urine samples using CE-MS were
conducted as described previously.4 CE-MS analysis was performed
with a P/ACE MDQ CE (Beckman Coulter, Fullerton, CA, USA) cou-
pled to a micro-TOF-MS (Bruker Daltonic, Bremen, Germany). Raw
MS data were evaluated using MosaFinder3 applying a probabilistic
clustering algorithm and using both isotopic distributions and conju-
gated masses for charge state determination. Normalization of the
CE-MS data was based on 29 collagen fragments that are generally
not affected by disease and serve as internal standards.3,4 Missing val-
ues were interpreted as zero. Identified HF biomarkers were assigned
in silico to sequenced peptides from the Human Urinary Proteome
database as described elsewhere.3 Further information on CE-MS anal-
ysis and peptide sequencing are provided in online supplementary
Methods.
Statistical analysis
Statistical analysis of urinary proteome profiles was performed using
the non-parametric Mann–Whitney test.16 A Benjamini–Hochberg
(BH) approach was employed to correct for multiple testing and the
false discovery rate. An adjusted P-value< 0.05 was considered statis-
tically significant. Only peptides that were found at >30% frequency
in cases or controls were examined, following the standard procedure
for defining disease-associated peptides. Correlation analysis was per-
formed using Spearman’s rank-order correlation.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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A B
Figure 1 Study design. Consort diagram for patient selection (A) as well as case-control matching workflow (B) are presented. BNP, B-type
natriuretic peptide; DBP, diastolic blood pressure; EF, ejection fraction; eGFR, estimated glomerular filtration rate; HF, heart failure; HFmrEF,
heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection
fraction; ICU, intensive care unit; NT-proBNP, N-terminal prohormone of pro-B-type natriuretic peptide; QC, quality control; SBP, systolic
blood pressure. *When performing case-control matching for each HF subtype, only controls (n = 773) that were matched in the comparison
of all patients with HF (n = 773) were considered. †When matching controls for patients with HFmrEF (n = 144), controls that have been
matched to HFrEF (n = 442) were not considered. ‡When matching controls to patients with HFpEF (n = 187), controls that were matched
in previous comparisons were excluded.
Unsupervised classification
Unsupervised clustering was performed using the R package
‘ConsensusClusterPlus’.17 Abundances for sequenced peptides
(independent of the significance level) were transformed to ranks,
and pairwise correlations between samples were calculated with
Spearman’s rank correlation coefficient. The correlation matrix was
submitted for agglomerative hierarchical clustering and using clus-
tering centroids and average linkage17 for a pre-defined number of
solutions (tested 2–8 clusters). Class assignment for each solution was
determined after 1000 permutations by resampling 95% of the sample
set, and the output was evaluated based on the consensus heat maps,
and cluster size.17 Principal component analysis (PCA) was conducted
on the same input data, using the base R function ‘prcomp()’ and the
argument scale = FALSE.
Bioinformatic analysis
Proteases responsible for the generation of the urinary peptide frag-
ments were predicted using the Proteasix tool.18 Predicted proteases




























. included as an input for functional analysis. Functional analysis was per-
formed with the Metascape,19 with Reactome pathway database used
as an ontology source (online supplementary Methods).
Results
Cohort characteristics
Among the 4970 participants included in the study after data
curation (Figure 1A), case-control matching resulted in the selection
of 773 patients with HF and 773 controls. Cases were stratified into
three subtypes: HFrEF (n = 442), HFmrEF (n = 144) and HFpEF
(n = 187). For each of the subtypes, the same number of controls
were matched (Figure 1B). The key matching characteristics were
similar between groups (Mann–Whitney test, P> 0.05), as shown
in Table 1. Patients with HFrEF, HFmrEF and HFpEF were matched
to each other, resulting in the selection of 117 individuals in
each group. The characteristics of the matched HF patients are
presented in online supplementary Table S1.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 List of the 20 peptides providing the greatest discrimination between patients with heart failure (HF, n = 773)
and matched controls (n = 773) as well as between matched controls and patients with HF with reduced (HFrEF,
n = 442), mid-range (HFmrEF, n = 144) and preserved ejection fraction (HFpEF, n = 187)
BH, Benjamini–Hochberg.
Peptides are ordered by increasing P-value in HF vs. controls.
Bold indicates top 20 peptides in individual comparisons.
Peptides higher in disease are labelled in green, lower in red.
aPeptides that did not pass the frequency threshold of 30%.
bPeptides that did not pass the P-value (BH adjusted) threshold of 0.05.
cPosttranslational modification: formylation (K).
dPosttranslational modification: deamination (N).
Urinary peptide differences in heart
failure
In this study, 3332 sequenced urinary peptides were investigated. A
total of 577 peptides differed significantly (BH adjustment P< 0.05)
between patients with HF and controls. The top 20 peptides
with the lowest P-value for differential expression between groups
are listed in Table 2, while their frequency, average abundance
and discrimination metrics [e.g. area under the receiver operating
characteristic curve (AUC), sensitivity, specificity] for distinguishing
between patients with HF and controls are provided in online
supplementary Table S2. AUCs were in a range between 0.65 and
0.75, with a median value of 0.7. Most of the peptides associated




















.. of 577 peptides (77%)] (Figure 2A), with collagen alpha-1(I) chain,
collagen alpha-1(III) chain and collagen alpha-2(I) chain represented
by the largest number of peptide fragments.
The results were consistent when investigating significant pep-
tides in HF patients stratified based on the original cohort (online
supplementary Table S3 and Figure S2), no batch effect was
detectable. Along these lines, our findings were also consistent
across patients with acute and chronic HF (online supplementary
Table S4 and Figure S3).
To assess the specificity of the findings for HF, we compared
the 577 peptides that were significantly different between patients
with HF and controls with the 273 peptides significantly associated
with CKD in a previous study (CKD27320). The biomarkers were
defined in two independent cohorts. Overlapping biomarkers
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.




Figure 2 Urinary peptides in heart failure (HF). (A) Volcano plot showing sequenced peptides identified between patients with HF and
matched controls. Directionality of the difference, magnitude as well as significance level [Benjamini–Hochberg (BH) adjusted P-value] are
displayed. Discrimination between collagen and non-collagen-derived peptides is provided. Peptides originated from proteins for which at
least 10 significant peptides were identified (P< 0.05, BH adjusted) when comparing all patients with HF and controls are colour-coded. (B)
Segregation of all study participants into two classes based on consensus clustering. (C) Graphical representation of the separation of the study
participants using principal component analysis. Principal component analysis was performed based on sequenced peptides detected in 30% of
samples (independent of the significance level), for which abundances were transformed to ranks. COL1A1, collagen alpha-1(I) chain; COL1A2,
collagen alpha-2(I) chain; COL2A1, collagen alpha-1(II) chain; COL3A1, collagen alpha-1(III) chain; FGA, fibrinogen alpha chain; HFmrEF, heart
failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction;
UMOD, uromodulin.
(71 peptides) as well as biomarkers unique for HF (506 peptides)
and CKD (202 peptides) were observed (online supplementary
Figure S4). The directional change in 32 of these 71 peptides
was opposite in HF and CKD, and only very weak correlation
between the fold-change in the peptide abundances observed
in CKD and HF was detectable (Spearman’s coefficient of rank
correlation (rho) = 0.25, P = 0.03, n = 71). Moreover, we inves-
tigated an association of peptide abundance with eGFR (used as
a continuous variable) in patients with HF. Seventy-three pep-
tides showed significant correlation (P< 0.05 BH adjusted), with
















.. adjusted) had rho values below 0.2, indicating very weak/negligible
relationship.
Using consensus clustering, the study participants were sep-
arated into two clusters. The majority of patients with HF
(65%) were allocated to cluster 2, while 83% of non-HF con-
trols were allocated to cluster 1 (Chi-squared test, P< 0.0001)
(Figure 2B). There was no separation based on HF subtype
(Chi-squared test, P> 0.05) (online supplementary Figure S5).
Findings applying PCA were similar, separating HF from con-
trols, but no evidence for discrimination between HF subtypes
(Figure 2C).
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Urinary peptide differences in heart
failure subtypes
There were only minor (or no) differences between the three HF
subtypes in pairwise comparisons. Only 13 peptides were signif-
icantly different between HFrEF and HFpEF (online supplemen-
tary Table S5), and none were detected with a P-value< 10−5.
AUCs were lower when comparing to those peptides differenti-
ating between patients with HF and controls, and were in a range
between 0.61 and 0.67, with a median value of 0.63.
Combining the urinary peptides with best discriminatory ability
(based on the AUC) into classifiers using support vector machines
did not enable reliable differentiation of the subtypes of HF (online
supplementary Figure S6), consistently with the results from unsu-
pervised clustering and PCA.
We further investigated differences in urinary peptides between
patients with HFrEF, HFmrEF and HFpEF and non-HF controls.
In matched comparisons, 476 peptides were significantly differ-
ent between patients with HFrEF and controls, 217 between
patients with HFmrEF and controls, and 261 between patients
with HFpEF and controls (Figure 3A). For many of these peptides,
the differences in abundance were detected with P-values< 10−5
(online supplementary Figure S7). The peptides that were most
significantly different between groups are listed in Table 2, while
further details of frequency, average abundance and discrimination
metrics are itemised in online supplementary Table S2. AUCs
were in a range between 0.64 and 0.77, with a median value of
0.69. A very high degree of consistency among the biomarkers
differentiating individual HF subtypes from controls appears evi-
dent (Figure 3B). A strong correlation between the fold changes in
peptide abundance when comparing control subjects to patients
with HFrEF or HFpEF was observed. Similar results were obtained
for patients with HFmrEF (Figure 3C).
Bioinformatic analysis
In silico protease analysis based on the peptides differing between
HF and controls resulted in the identification of 76 proteases. Eigh-
teen proteases that had at least one protease/cleavage site asso-
ciation reported in the literature and the percentage of cleavage
events above 1% (the most active) were shortlisted (online supple-
mentary Table S6). Shortlisted proteases included matrix metallo-
proteinases, calpains, cathepsins, and a disintegrin and metallopro-
teinase with thrombospondin motifs. Pathway enrichment analysis
based on the shortlisted predicted proteases, along with proteins
representing the peptides significantly different between patients
with HF and controls, was conducted. A network of significantly
enriched terms is presented in Figure 4. The analyses also indicated
a high degree of similarity in predicted proteases and enriched path-
ways between the three HF subtypes.
Discussion
This is the first investigation of the urinary proteomic profile of
more than 1500 patients with HF encompassing the full spectrum
of EF and non-HF controls (Graphical Abstract). While our data



















































































.. HF and non-HF controls for multiple urinary peptides, there were
very few differences among the different HF subtypes defined by
EF. Our study was also designed to identify HF specific peptides. To
limit the potential impact of co-existing diseases (CKD) and various
other factors (e.g. age) on urinary peptides, analysis was performed
in matched cohorts. Identified peptides significantly associated with
HF were clearly distinct from those peptides associated with CKD,
supporting their specificity for HF.
Our data demonstrate highly significant differences in multiple
urinary peptides between patients with HF and matched controls.
A frequency threshold of 30% was applied when defining peptides
significantly associated with HF. This threshold has been found
optimal in previous studies where multiple peptides were combined
into a classifier. Although biomarkers with low frequency are
of limited value on their own, they are beneficial in biomarker
panels since a higher number of biomarkers in the panel improves
stability.4,16 The most prominent alterations identified appear to
reflect dysregulation of collagen turnover, a well-known biological
process in HF,21 with specific collagen peptides affected in HF.
An explanation for this observation may be alterations in the
activity of proteases, which consequently would result in variation
in the abundance of peptides representing corresponding pairs of
substrates and products. These findings contrast to CKD, where
collagen-related peptides were consistently reduced.20
While we do not have a definitive explanation for the increases
and decreases of specific peptides and the exact mechanism behind
this observation is yet unknown, our findings are highly consistent
across individual comparisons. We found a general reduction in
fragments derived from network-forming collagens (collagen type
IV, and VIII) in patients with HF, suggesting that disturbance in
collagen degradation, possibly due to increasing stability of collagen
networks and cross-linking that protects them from degradation.
Our findings are consistent with the observation that all major
HF subtypes are associated with cardiac fibrosis and potentially
also fibrosis of other organs and tissues including arteries, where
collagen degradation may play a major role.
Circulating biomarkers reflecting collagen metabolism have
been shown to be associated with histologically proven myocardial
fibrosis in HF (carboxy-terminal propeptide of procollagen type
I, amino-terminal propeptide of procollagen type III, and collagen
type I telopeptide-to-serum matrix metalloproteinase-1 ratio).21
However, these peptides are not specific for cardiac fibrosis and
may indicate abnormalities of collagen turnover in other organs.22
Urinary peptides also may reflect molecular changes induced
by systemic conditions or localised diseases. While we cannot
confirm the origin of the specific urinary peptides in this study,
the fact that they differ largely from those identified in patients
with CKD suggests that the changes observed are specific for HF.
Although this was an historical comparison, biomarkers associated
with CKD20 and HF (as defined in this study) were identified
using the same technological platform. The 273 biomarkers for
CKD have been consistently used over more than 10 years.
Therefore, the limited overlap between CKD and HF biomarkers
cannot be due to changes in biomarker definition over time. In
addition, there was a very weak association of the abundance
of HF-associated peptides with eGFR in patients with HF, which
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.




Figure 3 Urinary peptides across heart failure (HF) subtypes. (A) Comparison of the sequenced peptides that significantly differ between
analysed sub-groups. (B) Heat map presenting log2 transformed fold-changes for 20 most significant peptides across HF subtypes and between
all patients with HF in comparison to controls (Table 2). (C) Correlation of peptides significantly associated with HF with preserved (HFpEF),
reduced (HFrEF) and mid-range (HFmrEF) ejection fraction when comparing the fold-change observed in HFpEF vs. controls, HFrEF vs. controls
and HFmrEF vs. controls. Commonly significant peptides between comparisons were included.
further supports their specificity for HF. It is well-recognised
that HF and CKD commonly co-exist, share many common
risk factors, and are expected to share common mechanisms.23
However, our study was designed to find peptides that are specific
for HF (and not other comorbidities like CKD). To eliminate the
impact of CKD (and other variables) on urinary peptides, the
urinary peptide profiles from participants with HF and controls
were carefully matched to, among others, obtain an even distri-












.. specific for CKD to be eliminated. This may partially explain
the low overlap between HF and CKD-associated peptides,
since impact of CKD was removed through patients matching.
Investigation of overlapping urinary peptides in HF patients with
CKD and without CKD was beyond the scope of this work and
will be examined in a future study. Urinary proteome analysis
appears to be biased towards identification of collagen fragments.2
Collagen peptides are enriched in urine, possibly because they
are not reabsorbed in the renal tubules.2 However, in addition
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 4 Legent on next page.
to changes in specific collagen fragments, we detected alterations
in peptides originating from non-collagen proteins. We specifi-
cally focused on proteins represented by peptides that showed
a consistent directional change in abundance. Among proteins
represented by peptides increased in patients with HF, several pro-
teins present in blood were found, including beta-2-microglobulin
(a component of the major histocompatibility antigen indicat-
ing activation of the immune system and widely considered
to reflect renal tubular function), 35 kDa inter-alpha-trypsin
inhibitor heavy chain H4 (an acute-phase protein participat-
ing in inflammatory responses to trauma), apolipoprotein C-III
(involved in triglyceride homeostasis), and matrix Gla pro-
tein (an inhibitor of vascular mineralization involved in bone
organization). Excretion of proteins in urine may reflect not
only localized kidney disease, but also vascular endothe-
lial dysfunction.24 As kidney function was adjusted for in
the case-control matching, increased abundance of peptides
originating from plasma proteins may indicate vascular endothe-






























.. Besides pathways reflecting alteration in collagen turnover (such
as collagen degradation, activation of matrix metalloproteinases,
anchoring fibril formation), the second most prominent finding
was pathways associated with immune response, mostly innate
immunity. Our analysis revealed alterations in Toll-like receptor
(TLR) cascades, the involvement of which in the inflammatory
response in HF is well recognised.26 TLR signalling triggers inflam-
mation leading to maladaptive wound healing and fibrosis. Besides
impact of HF on TLRs, urinary proteomics data also indicate
dysregulation of pathways representing effector systems of the
innate immunity, including neutrophil degranulation and comple-
ment cascade. Neutrophils play a role in the early phase of cardiac
healing upon myocardial injury through clearance of dead cells
and polarisation of macrophages, while neutrophil dysregulation
leads to heart dysfunction and failure.27 Abnormal complement
activation promotes inflammation and tissue damage, and has been
reported in patients with HF.28
Surprisingly, the three HF subtypes could not be separated
based on urinary peptide analysis, whereas the differences
between patients with HF and non-HF controls were obvious.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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This implies that the molecular alterations in urine are indifferent
to the EF. In line with our findings, it has been proposed that
changes in fibrillar collagen (collagen type I) turnover are common
in HF independent of EF.21 This suggests that EF, although a
cornerstone in HF management, may not be related to specific
molecular changes, further supporting concerns about the validity
of the current definitions of HF subtypes.29 Our findings may also
help explain why developing effective therapies for certain HF
subtypes using EF has proved challenging. It may be worth inves-
tigating the potential of subtyping HF patients based on molecular
alterations, analogous to the approach established in oncology.30
Characterisation and subtyping of HF through the clustering of
urinary data (alone or as a part of multi-omics approach) may
enable more precise definition of disease subtypes, leading to
the development of more effective drugs for sub-populations of
patients and thus personalised treatment. Although the number
of urinary peptides that differed significantly from controls was
highest amongst patients with HFrEF, 84% of peptides differing
between HFmrEF and controls, and 78% differing between HFpEF
and controls overlapped with those differing between HFrEF
and controls, with similar quantitative changes. The difference in
numbers of significant peptides is likely due to the smaller number
of patients in the HFmrEF and HFpEF groups. The increase in the
number of significant markers with increasing samples size has
been described previously, with the plateau reached at sample sizes







































. Collectively, considering the complex pathophysiology underly-
ing HF, urinary proteomics may have an advantage to better profile
fibrosis and also systemic impact of HF in comparison to single
biomarkers. Based on urinary peptide alterations, it appears that
targeting collagen degradation may be feasible and a novel approach
to combat fibrosis. Further studies are planned to evaluate the
applicability of the biomarkers we have identified for detection
of patients with HF. One aim is investigating if the biomarkers
identified here would enable early detection of HF, prior to the
onset of symptoms, to enable timely (ideally preventive) interven-
tion. In addition, we aim at testing the value of the biomarkers
described here in predicting disease progression. Further, testing
of the biomarkers for their value in predicting drug response, as
was e.g. shown for CKD273,31 seems a valid approach. Based on
these results the ultimate goal is application of the findings to strat-
ify patients in clinical trials based on their proteomics profile to
target treatment. The use of the urinary proteomic data alone, or
as a part of multi-omics phenotyping, may ultimately lead to better
characterization of disease pathophysiology and may help identify-
ing targets for novel therapeutic strategies.
Study strengths and limitations
The strength of our study was a large sample size covering patients
with HF across the full range of EF. As a result, confidence in
the validity of the findings is very high. Moreover, all urinary pep-
tide datasets were acquired using the same analytical platform
Figure 4 Enrichment analysis based on Reactome pathways. (A) Network of enriched terms. Graphical representation of pathways significantly
enriched based on the predicted proteases and proteins representing the urinary peptides. Networks are coloured based on cluster ID,
the thickness of the edge represents the similarity score. The most significant term from each cluster was selected as label and for those
terms, P-value corrected using Banjamini–Hochberg (BH) procedure is given. Among the most prominent findings, significant enrichment for
pathways related to collagen turnover (highlighted in blue) and immune response (highlighted in orange) was observed. (B) Parental proteins and
predicted proteases annotated to the most significant terms. A1BG, alpha-1B-glycoprotein; ADAMTS4, A disintegrin and metalloproteinase
with thrombospondin motifs 4; AHSG, alpha-2-HS-glycoprotein; APOA1, apolipoprotein A-I; B2M, beta-2-microglobulin form pI 5.3; C3,
complement C3; CAPN1, calpain-1 catalytic subunit; CAPN2, calpain-2 catalytic subunit; CD99, CD99 antigen; CDH1, cadherin 1; CFB,
complement factor B; CHGB, secretogranin-1; CLU, clusterin; COL11A1, collagen alpha-1(XI) chain; COL11A2, collagen alpha-2(XI) chain;
COL14A1, collagen alpha-1(XIV) chain; COL15A1, collagen alpha-1(XV) chain; COL16A1, collagen alpha-1(XVI) chain; COL17A1, collagen
alpha-1(XVII) chain; COL18A1, collagen alpha-1(XVIII) chain; COL19A1, collagen alpha-1(XIX) chain; COL1A1, collagen alpha-1(I) chain;
COL1A2, collagen alpha-2(I) chain; COL22A1, collagen alpha-1(XXII) chain; COL23A1, collagen alpha-1(XXIII) chain; COL25A1, collagen
alpha-1(XXV) chain; COL28A1, collagen alpha-1(XXVIII) chain; COL2A1, collagen alpha-1(II) chain; COL3A1, collagen alpha-1(III) chain;
COL4A1, collagen alpha-1(IV) chain; COL4A2, collagen alpha-2(IV) chain; COL4A3, collagen alpha-3(IV) chain; COL4A4, collagen alpha-4(IV)
chain; COL4A5, collagen alpha-5(IV) chain; COL4A6, collagen alpha-6(IV) chain; COL5A1, collagen alpha-1(V) chain; COL5A2, collagen
alpha-2(V) chain; COL5A3, collagen alpha-3(V) chain; COL6A1, collagen alpha-1(VI) chain; COL6A2, collagen alpha-2(VI) chain; COL7A1,
collagen alpha-1(VII) chain; COL8A1, collagen alpha-1(VIII) chain; COL8A2, collagen alpha-2(VIII) chain; COL9A2, collagen alpha-2(IX) chain;
COL9A3, collagen alpha-3(IX) chain; CTSB, cathepsin B; CTSK, cathepsin K; CTSL, cathepsin L1; CTSS, cathepsin S; EFNA1, ephrin-A1;
F2, thrombin light chain; FGA, fibrinogen alpha chain; FGB, fibrinogen beta chain; GSN, gelsolin; H2BC12, histone H2B type 1-K; HBA1,
haemoglobin subunit alpha; HBB, haemoglobin subunit beta; HSPB1, heat shock protein beta-1; INS, insulin; ITIH4, 35 kDa inter-alpha-trypsin
inhibitor heavy chain H4; LMAN2, vesicular integral-membrane protein VIP36; MAN1A1, mannosyl-oligosaccharide 1;2-alpha-mannosidase IA;
MASP2, mannan-binding lectin serine protease 2; MMP1, interstitial collagenase; MMP12, macrophage metalloelastase; MMP13, collagenase 3;
MMP14, matrix metalloproteinase-14; MMP2, 72 kDa type IV collagenase; MMP25, matrix metalloproteinase-25; MMP3, stromelysin-1; MMP7,
matrilysin; MMP8, neutrophil collagenase; MMP9, matrix metalloproteinase-9; ORM1, alpha-1-acid glycoprotein 1; PCDH7, protocadherin-7;
PGRMC1, membrane-associated progesterone receptor component 1; PIGR, polymeric immunoglobulin receptor; PLG, plasminogen; PPP3CA,
serine/threonine-protein phosphatase; S100A8, protein S100-A8; S100A9, protein S100-A9; SERPINA1, alpha-1-antitrypsin; SPP1, osteopontin;
TMSB4X, thymosin beta-4; TTR, transthyretin; TUBB3, tubulin beta-3 chain; UMOD, uromodulin; VGF, neurosecretory protein VGF. *In silico
predicted proteases.
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(CE-MS), with analysis and data processing performed according to
ISO13485 standards. This allows for generation of highly compara-
ble data, enabling comparisons in the wide spectrum of conditions.
Limitations included that individual patient data were derived
from the different cohorts of HF patients and controls enrolled
at multiple clinical centres. However, case-control matching for
clinical/demographical variables known to have an impact on uri-
nary peptides allowed to harmonise the data in the respective
comparisons. Although efforts were made to collect urine sam-
ples on the same day as other study assessments, this may not
have been the case for every participant. There was no stan-
dard operating procedure applied for the collection of all urine
samples, specifically there were no requirements made for an
early morning or mid-stream sample. However, previous stud-
ies based on CE-MS have shown good reproducibility of data,
even if sampling is not fully standardized.3,4 On the other hand,
inclusion of patients from different cohorts can also be seen
as a strength, as our findings were consistent across different
cohorts.
In addition, this was a retrospective cross-sectional analysis.
Therefore, for non-HF controls, the information on measurements
performed for patients suspicious for HF (e.g. NT-proBNP, BNP,
EF, etc.) is frequently missing. Our study was not designed to
compare the diagnostic performance of urinary peptides with
NT-proBNP and BNP. Those plasma biomarkers were used as
one of the criteria for defining HF and thus inclusion/exclusion
of patients in our study, preventing an unbiased comparison.
A previous study demonstrated that a set of urinary pep-
tides had similar utility as BNP in diagnosing patients with HF,
while a combination of BNP with urinary peptides provided
additional diagnostic information.7 Information about medica-
tions (e.g. angiotensin-converting enzyme inhibitors, angiotensin
receptor–neprilysin inhibitor) was not available for all cohorts,
and thus was not taken into account. Similar applies to information
on disease aetiology (ischaemic or non-ischaemic) and thus, those
patient groups were not discriminated in our study. Moreover,
associations between urinary markers and clinical outcomes were
not investigated. However, in a recent study the value of urinary
collagen type I peptides in predicting outcome in HF has been
demonstrated.32
Conclusions
Heart failure is consistently associated with differences in urine
peptides, compared to non-HF controls, reflecting fibrosis and
the systemic impact of HF. HF subtypes based on left ventricular
phenotype, although clinically different, are very similar at the
level of urinary peptides. Definition of HF subtypes based on
molecular changes, similar to oncology, may be more appropriate,
especially when aiming for personalized intervention. Application
of urinary peptides to support management of patients with
HF, although feasible, requires further assessment in prospective
trials, to investigate the potential for early detection, molecular





















































































Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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